Immunomodulators Under Evaluation for the Treatment of COVID-19
Last Updated: February 11, 2021
See Therapeutic Management of Patients with COVID-19 for the COVID-19 Treatment Guidelines Panel’s (the Panel’s) recommendations on the use of the following:
See additional recommendations on the use of baricitinib below.
See Statement on the Use of Tocilizumab (and Other Interleukin-6 Inhibitors) for the Panel’s recommendations on the use of tocilizumab and sarilumab.
There are insufficient data for the Panel to recommend either for or against the use of the following immunomodulators for the treatment of COVID-19:
The Panel recommends against the use of the following immunomodulators for the treatment of COVID-19, except in a clinical trial:
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = One or more randomized trials without major limitations; IIa = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion